Retinoic acids exhibit anti-fibrotic activity through the inhibition of 5-lipoxygenase expression in scleroderma fibroblasts

Journal of Dermatology

Volumn 38, Issue 4, 2011, Pages 345-353

  Xiao, Rong ^a,b   Yoshida, Nobuyo ^a   Higashi, Yuko ^a   Lu, Qian Jin ^b   Fukushige, Tomoko ^a   Kanzaki, Tamotsu ^a   Kanekura, Takuro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

5 lipoxygenase; collagen; connective tissue growth factor; retinoic acid; scleroderma

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; RETINOIC ACID; TRANSFORMING GROWTH FACTOR BETA1; COLLAGEN; CTGF PROTEIN, HUMAN; INDOLE DERIVATIVE; LIPOXYGENASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; WESTERN BLOTTING; CELL CULTURE; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; SKIN; SYSTEMIC SCLEROSIS;

ADULT; AGED; ARACHIDONATE 5-LIPOXYGENASE; CELLS, CULTURED; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; FIBROBLASTS; GENE EXPRESSION; HUMANS; INDOLES; LIPOXYGENASE INHIBITORS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA1; TRETINOIN;

EID: 79953096818     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.00993.x     Document Type: Article

References (41)

1. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205. (Pubitemid 18073738)
2. Mauch C, Eckes B, Hunzelmann N, Oono T, Kozlowska E, Krieg T,. Control of fibrosis in systemic scleroderma. J Invest Dermatol 1993; 100: 92S-96S. (Pubitemid 23035912)
3. Kovacs EJ, Dipietro LA,. Fibrogenic cytokines and connective tissue production. FASEB J 1994; 8: 854-861. (Pubitemid 24268877)
4. Lewis RA, Austen KF, Soberman RJ,. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323: 645-655. (Pubitemid 20280195)
5. Henderson WR Jr,. The role of leukotrienes in inflammation. Ann Intern Med 1994; 121: 684-697.
6. Baud L, Perez J, Denis M, Ardaillou R,. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J Immunol 1987; 138: 1190-1195. (Pubitemid 17017905)
7. 4 on human airway smooth muscle cell proliferation, matrix expression, and contraction In vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 1998; 19: 453-461. (Pubitemid 128354215)
8. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN,. Leukotrien and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171-1176. (Pubitemid 17131222)
9. Wilborn J, Bailie M, Coffey M, Burdick M, Strieter R, Peters-Golden M,. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996; 97: 1827-1836.
10. Meghji S, Sandy JR, Harvey W, Henderson B, Ali N,. Stimulation of bone collagen and non-collagenous protein synthesis by products of 5- and 12-lipoxygenase: determination by use of a simple quantitative assay. Bone Miner 1992; 18: 119-132.
11. 4 to rat lung fibroblasts and stimulation of collagen synthesis in vitro. Biochemistry 1988; 27: 2846-2853.
12. 4 upregulates collagenase expression and synthesis in human lung fibroblasts. Biochim Biophys Acta 1994; 1224: 168-174. (Pubitemid 24345031)
13. Yocum DE, Lafyatis R, Remmers EF, Schumacher HR, Wilder RL,. Hyperplastic synoviocytes from rats with streptococcal cell wall-induced arthritis exhibit a transformed phenotype that is thymic-dependent and retinoid inhibitable. Am J Pathol 1988; 132: 38-48.
14. Haraoui B, Wilder RL, Allen JB, Sporn MB, Helfgott RK, Brinckerhoff CE,. Dose-dependent suppression by the synthetic retinoid, 4-hydroxyphenyl retinamide, of streptococcal cell wall-induced arthritis in rats. Int J Immunopharmacol 1985; 7: 903-916. (Pubitemid 16213259)
15. Oikarinen H, Oikarinen AI, Tan EM, et al. Modulation of procollagen gene expression by retinoids. Inhibition of collagen production by retinoic acid accompanied by reduced type I procollagen messenger ribonucleic acid levels in human skin fibroblast cultures. J Clin Invest 1985; 75: 1545-1553. (Pubitemid 15041447)
16. Ohta A, Uitto J,. Procollagen gene expression by scleroderma fibroblasts in culture. Inhibition of collagen production and reduction of pro alpha 1(I) and pro alpha 1(III) collagen messenger RNA steady-state levels by retinoids. Arthritis Rheum 1987; 30: 404-411. (Pubitemid 17080777)
17. Uhlman A, Brauninger W,. Therapeutic results with the aromatic retinoid (Tigason) in Sharp syndrome and progressive scleroderma. Z Hautkr 1985; 60: 774-776.
18. Delany AM, Brinckerhoff CE,. The synthetic retinoid (4-hydroxyphenyl) retinamide decreases collagen expression in vitro and in the tight-skin mouse. Arthritis Rheum 1993; 36: 983-993. (Pubitemid 23201114)
19. Ikeda T, Uede K, Furukawa F,. The vitamin A derivative etretinate improves skin sclerosis in patients with systemic sclerosis. J Dermatol Sci 2004; 34: 62-66. (Pubitemid 38134476)
20. 2 production in human fibroblasts. J Immunol 1990; 145: 4245-4251.
21. Krieg T, Meurer M,. Systemic sclerosis: clinical and pathophysiological aspects. J Am Acad Dermatol 1988; 18: 457-481. (Pubitemid 18082461)
22. Geppert T,. Southwestern internal medicine conference: clinical features, pathogenic mechanisms, and new developments in treatment of systemic sclerosis. Am J Med Sci 1990; 299: 193-209. (Pubitemid 20085239)
23. LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM,. A strategy for determining the pathogenesis of systemic sclerosis: is transforming growth factor b the answer? Arthritis Rheum 1989; 32: 817-825. (Pubitemid 19181003)
24. 4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. Arthritis Rheum 2003; 48: 1639-1646. (Pubitemid 36682372)
25. Kowal-Bielecka O, Kowal K, Distler O, et al. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 2005; 52: 3783-3791. (Pubitemid 41798216)
26. Kowal-Bielecka O, Distler O, Neidhart M, et al. Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. Arthritis Rheum 2001; 44: 1865-1875. (Pubitemid 32758235)
27. Beno DW, Mullen J, Davis BH,. Lipoxygenase inhibitors block PDGF-induced mitogenesis: a MAPK-independent mechanism that blocks fos and egr. Am J Physiol 1995; 268: C604-C610.
28. Chen A, Beno DW, Davis BH,. Suppression of Stellate Cell Type I Collagen gene Expression Involves AP-2 Transmodulation of Nuclear Factor-1-dependent Gene Transcription. J Biol Chem 1996; 271: 25994-25998. (Pubitemid 26347436)
29. Peters-Golden M, Bailie M, Marshall T, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002; 165: 229-235. (Pubitemid 34084463)
30. Smith RS, Smith TJ, Blieden TM, Phipps RP,. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997; 151: 317-322.
31. Kahler CM, Herold M, Wiedermann CJ,. Substance P: a competence factor for human fibroblast proliferation that induces the release of growth-regulatory arachidonic acid metabolites. J Cell Physiol 1993; 156: 579-587. (Pubitemid 23269876)
32. Kahler CM, Herold M, Reinisch N, Wiedermann CJ,. Interaction of substance P with epidermal growth factor and fibroblast growth factor in cyclooxygenase-dependent proliferation of human skin fibroblasts. J Cell Physiol 1996; 166: 601-608.
33. Chambon P,. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10: 940-954. (Pubitemid 26285969)
34. Xu Q, Lucio Cazana J, Kitamura M, Ruan X, Fine LG, Normal JT,. Retinoids in nephrology: promises and pitfalls. Kidney Int 2004; 66: 2119-2131. (Pubitemid 41115275)
35. Takehara K,. Hypothesis: pathogenesis of systemic sclerosis. J Rheumatol 2003; 30: 755-759.
36. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M,. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998; 110: 47-51. (Pubitemid 28086062)
37. Ihn H, Yamane K, Kubo M, Tamaki K,. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001; 44: 474-480.
38. Frazier K, Williams S, Kothapalli D, et al. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996; 107: 404-411. (Pubitemid 26284351)
39. Xiao R, Liu FY, Luo JY, et al. Effect of small interfering RNA on the expression of connective tissue growth factor and type I and III collagen in skin fibroblasts of patients with systemic sclerosis. Br J Dermatol 2006; 155: 1145-1153. (Pubitemid 44729987)
40. Quan T, He T, Kang S, et al. Connective tissue growth factor: expression in human skin in vivo and inhibition by ultraviolet irradiation. J Invest Dermatol 2002; 118 (3): 402-408. (Pubitemid 34227155)
41. Sato S, Nagaoka T, Hasegawa M, et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000; 27: 149-154. (Pubitemid 30058642)